ERBB2 and urothelial carcinoma: An open-label, single-arm, multicenter phase Ib/II clinical trial demonstrated that four patients with locally advanced urothelial carcinoma and HER2 IHC 1+/2+/3+ achieved a cCR rate of 100% after receiving DV plus tislelizumab as neoadjuvant therapy (Wen, 2022).